Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisler, T.
Right arrow Articles by Calne, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisler, T.
Right arrow Articles by Calne, D. B.
NEUROLOGY 1981;31:1368
© 1981 American Academy of Neurology

Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine

Toomas Eisler, M.B., Russell P. Hall, M.D., Kusum A.R. Kalavar, M.D. and Donald B. Calne, D.M., F.R.C.P.

Experimental Therapeutics Branch (Drs. Eisler and Calne), National Institute of Neurological and Communicative Disorders and Stroke, and the Dermatology Branch (Dr. Hall), and the Laboratory of Pathology (Dr. Kalavar), National Cancer Institute, Bethesda, MD.

In a previous report about the chronic use of bromocriptine in Parkinson disease, a distinctive cutaneous eruption was noted and termed "erythromelalgia." This eruption has occurred in 9 of 110 patients on chronic bromocriptine therapy; histopathologic examination in 3 patients showed a prominent perivascular lymphocytic infiltration and perivascular edema of the dermis, without frank vasculitis. This is a reversible unwanted effect of bromocriptine therapy.

Address correspondence and reprint requests to Dr. Calne, Building 10, Room 6D20, National Institutes of Health, Bethesda, MD 20205.

Accepted for publication February 11, 1981.




This article has been cited by other articles:


Home page
 Arch DermatolHome page
M. D. P. Davis, W. M. O'Fallon, R. S. Rogers III, and T. W. Rooke
Natural History of Erythromelalgia: Presentation and Outcome in 168 Patients
Arch Dermatol, March 1, 2000; 136(3): 330 - 336.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M M Pinter, O Pogarell, and W H Oertel
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study
J. Neurol. Neurosurg. Psychiatry, April 1, 1999; 66(4): 436 - 441.
[Abstract] [Full Text]

Home page
 NEJMHome page
F. J. Fernandez-Fernandez, J.A. Garrido, M. Hauben, J. P.H. Drenth, J. J. Michiels, L. Hughes-Davies, R. S. Stern, and J. C. Roujeau
Severe Adverse Cutaneous Reactions to Drugs
N. Engl. J. Med., April 6, 1995; 332(14): 959 - 960.
[Full Text]

Home page
 NEJMHome page
D. B. Calne
Treatment of Parkinson's Disease
N. Engl. J. Med., September 30, 1993; 329(14): 1021 - 1027.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.